Renovaro Biosciences Inc. reported earnings results for the first quarter ended September 30, 2023. For the first quarter, the company reported net loss was USD 9.18 million compared to USD 7.7 million a year ago. Basic loss per share from continuing operations was USD 0.14 compared to USD 0.14 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.53 USD | -10.00% | -29.49% | -51.74% |
Apr. 24 | Renovaro's RenovaroCube Amends Agreement to Acquire 100% Stake in Cyclomics | MT |
Apr. 18 | Renovaro Inc. Announces Geert Kazemier, MD, PhD, as the New Chairman of its Scientific Advisory Board | CI |
1st Jan change | Capi. | |
---|---|---|
-51.74% | 220M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.74B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- RENB Stock
- News Renovaro Inc.
- Renovaro Biosciences Inc. Reports Earnings Results for the First Quarter Ended September 30, 2023